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ysis, was defined as the first infection identified following
a gap of at least 30 days in antibiotic use. The treatment
episode ended when there were no additional antibiotics
prescribed or infection-related outpatient medical visits
for 21 consecutive days. The costs of antibiotics, visits,
and tests were documented over the course of the epi-
sode. RESULTS: A total of 30,562 patients (11,798 with
sinusitis, 5,636 with otitis media, 7,310 with pharyngitis,
and 5,818 with bronchitis) met the study inclusion crite-
ria. For sinusitis, OM, and pharyngitis, penicillins were
the most widely prescribed antibiotics, followed by mac-
rolides, sulfonamides, cephalosporins, penicillin/B-lacta-
mase inhibitors, tetracyclines and fluroquinilones. Mac-
rolides were the most commonly used antibiotic for
bronchitis (48% of patients). For patients requiring a
switch to a different antibiotic, macrolides were the most
frequent choice. The overall costs per episode were $97
for pharyngitis, $114 for both OM and sinusitis, and
$133 for bronchitis. The proportion of total costs related
to follow-up treatment ranged from 19% for pharyngitis
to 32% for OM. Antibiotics accounted for 19% (for
pharyngitis) to 29% (for sinusitis) of overall costs. CON-
CLUSIONS: The costs of treatment episodes for RTIs are
fairly substantial and vary by condition. While the initial
encounter accounts for the majority of the costs, the ex-
penses associated with the need for additional treatment
are important to consider.
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OBJECTIVE: In addition to information about efficacy
and safety, decision-makers are interested in information
about the impact of new drug treatments on health care
costs. The objective is to determine the impact of using
gatifloxacin versus levofloxacin on total costs among
outpatient adults with community-acquired pneumonia
(CAP). METHODS: Patients were randomized to receive
either gatifloxacin (GAT) or levofloxacin (LEV) once
daily. Data were collected on efficacy, safety, and medi-
cal care resource use from 163 GAT and 176 LEV clini-
cally evaluable patients. Medical care resource use infor-
mation included the dose and duration of the study and
concomitant medications, duration of intensive care unit
(ICU) and non-ICU hospital stay, and number of outpa-
tient physician visits. We used a multivariate regression
analysis to determine the impact of treatment on total
costs. The dependent variable was the logarithm of total
costs to adjust for the left skewness found in the cost
data. The regression analysis controlled for disease sever-
ity, admission to the hospital on the day of (or before)
randomization, and prognostic factors (including age,
presence of comorbidities, and a previous CAP episode
within the last 12 months). RESULTS: GAT achieved a
cure rate of 96% compared to 94% for LEV. Based on
results from the multivariate regression analysis, patients
in the GAT arm could expect total costs that were ap-
proximately 8% lower (on average) than the total costs
incurred by patients in the LEV arm. Patients admitted to
the hospital on the day of (or before) randomization
could expect total costs that were nearly 51 times higher.
Hospital admission on the day of (or before) randomiza-
tion was the only statistically significant driver of ex-
pected total cost. CONCLUSION: GAT shows a trend to
be less costly and have a higher cure rate than LEV for
outpatients with CAP.
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BACKGROUND: In the field of respiratory tract infec-
tions (RTI), concern about the efficiency of various treat-
ments has increased with the introduction of newer anti-
biotics often associated with higher acquisition costs.
These include second-generation macrolides and fluoro-
quinolones, which constitute alternative strategies to
amoxicillin and erythromycin. OBJECTIVES: To evalu-
ate, from a cost-efficacy standpoint, how these newer
agents compare with each other in the treatment of com-
munity acquired RTI in adults. METHODS: Cost-effi-
cacy analyses were done using decision-analysis tech-
niques based on efficacy and safety data of published
clinical trials. The analyses were performed from the per-
spective of a provincial third-party payer. Costs consid-
ered were those of antibiotics, physicians and pharma-
cists services and diagnostic procedures. RTI for which
analyses were performed are: bronchitis, community ac-
quired pneumonia, otitis media, pharyngitis and sinusitis.
Specific antibiotics compared were: azithromycin, cipro-
floxacin, clarithromycin, grepafloxacin, levofloxacin and
ofloxacin. RESULTS: Following a review of the literature
using Medline and Current Contents, 98 articles pub-
lished between January 1986 and December 1999 met
the inclusion criteria and provided efficacy and safety
data for the analyses. Efficacy rates for each antibiotic
did not differ strikingly and various dosages did not nec-
essarily have an impact on efficacy rates. Cost-efficacy
analyses indicate that, among the antibiotics studied, the
lowest cost-efficacy ratios were associated with either
azithromycin or clarithromycin at a dose of 250mg twice
daily. Azithromycin represented the preferred strategy for
the ambulatory treatment of community-acquired pneu-
monia and otitis media, while clarithromycin at a dose of
